Stocks · News reference
Veradermics Announces Investor Call to Review Phase 3 Clinical Trial Results for VDPHL01
Veradermics, Incorporated announced it will host an investor call and live webcast on November 9, 2026, to discuss topline results from its Phase 3 clinical trial of VDPHL01.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results
Veradermics reports positive Phase 2/3 trial data for its oral hair loss pill, paving the way for potential FDA approval. MANE shares rise.
8-K filing — Veradermics, Inc (MANE)
Filed: 2026-11-09 AccNo: 0001827635-26-000038 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Veradermics Announces Topline Results from Phase 3 Clinical Trial of VDPHL01
Veradermics, Incorporated reported topline results from its registration-directed Phase 3 clinical trial (Study '302') evaluating VDPHL01 for the treatment of pattern hair loss.
Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss
Connecticut Innovations Reports Record Venture Proceeds Driven by Veradermics IPO
Connecticut Innovations announced record-breaking quarterly venture proceeds of $51.4 million, largely attributed to the initial public offering of its portfolio company, Veradermics, Incorporated.